Last July, Medtronic (Minneapolis) received an FDA nod to begin a landmark study of its Symplicity renal denervation system in the U.S., allowing the company to enroll patients in SYMPLICITY HTN-3 to evaluate the safety and effectiveness of renal denervation with the Symplicity catheter in patients with resistant hypertension (Medical Device Daily, July 13, 2011). Now, Medtronic is taking it a step further two steps, actually with the start of two clinical initiatives evaluating the broader, real-world clinical use of the device across multiple conditions.